/NVS

NVS Stock - Novartis AG

Q: What is the analyst price target for NVS?

Analyst price target information is not currently available for NVS.

Q: What is NVS's market cap?

Market capitalization information is not currently available for NVS.

Healthcare|Drug Manufacturers - General|NYSE

$141.61-0.15%

$0.21 (-0.15%) • Jan 13

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

HOLD

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

100

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+-10.3%upside

Target: $127.02

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for NVS

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2020

FY2021

FY2022

FY2023

FY2024

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta0.45

52W High$143.49

52W Low$97.39

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2024	FY2023	FY2022	FY2021	FY2020
Revenue	$51.72B	$46.66B	$43.46B	$43.97B	$49.90B
Gross Profit	$38.90B	$34.19B	$31.88B	$32.24B	$34.78B
Gross Margin	75.2%	73.3%	73.4%	73.3%	69.7%
Operating Income	$14.54B	$9.77B	$7.95B	$10.06B	$10.15B
Net Income	$11.94B	$14.85B	$6.96B	$24.02B	$8.07B
Net Margin	23.1%	31.8%	16.0%	54.6%	16.2%
EPS	$5.92	$7.15	$3.19	$10.71	$3.54

Company Overview

Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatology, respiratory, cardiovascular, renal, and metabolism medicine products. The Sandoz segment develops, manufactures, and markets finished dosage form medicines; active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties; and retail generics and anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.

Visit Website

Earnings History & Surprises

NVS

Beat Rate

83%

Last 18 quarters

Avg Surprise

+3.8%

EPS vs Estimate

Beats / Misses

15/3

Last 12 quarters

Latest EPS

$2.25

Q4 2025

EPS Surprise History

Q1 24

-6.7%

$1.53vs$1.64

Q2 24

+4.0%

$1.80vs$1.73

Q3 24

+4.2%

$1.97vs$1.89

Q4 24

+6.2%

$2.06vs$1.94

Q1 25

+10.0%

$1.98vs$1.80

Q2 25

+7.5%

$2.28vs$2.12

Q3 25

+1.7%

$2.42vs$2.38

Q4 25

-0.4%

$2.25vs$2.26

Beat Estimate

Missed Estimate

Quarterly EPS Details

Period	Report Date	Estimated EPS	Actual EPS	Surprise	Result
Q2 2026	Apr 27, 2026	—	—	—	—
Q1 2026	Jan 30, 2026	$1.97	—	—	—
Q4 2025	Oct 28, 2025	$2.26	$2.25	-0.4%	✗ MISS
Q3 2025	Jul 17, 2025	$2.38	$2.42	+1.7%	✓ BEAT
Q2 2025	Apr 29, 2025	$2.12	$2.28	+7.5%	✓ BEAT
Q1 2025	Jan 31, 2025	$1.80	$1.98	+10.0%	✓ BEAT
Q4 2024	Oct 29, 2024	$1.94	$2.06	+6.2%	✓ BEAT
Q3 2024	Jul 18, 2024	$1.89	$1.97	+4.2%	✓ BEAT
Q2 2024	Apr 23, 2024	$1.73	$1.80	+4.0%	✓ BEAT
Q1 2024	Jan 31, 2024	$1.64	$1.53	-6.7%	✗ MISS
Q4 2023	Oct 24, 2023	$1.70	$1.74	+2.4%	✓ BEAT
Q3 2023	Jul 18, 2023	$1.68	$1.83	+8.9%	✓ BEAT
Q2 2023	Apr 25, 2023	$1.55	$1.71	+10.3%	✓ BEAT
Q1 2023	Feb 1, 2023	$1.42	$1.51	+6.3%	✓ BEAT
Q4 2022	Oct 25, 2022	$1.57	$1.58	+0.6%	✓ BEAT
Q3 2022	Jul 19, 2022	$1.51	$1.56	+3.3%	✓ BEAT
Q2 2022	Apr 26, 2022	$1.44	$1.46	+1.4%	✓ BEAT
Q1 2022	Feb 2, 2022	$1.44	$1.40	-2.8%	✗ MISS
Q4 2021	Oct 26, 2021	$1.65	$1.71	+3.6%	✓ BEAT
Q3 2021	Jul 21, 2021	$1.53	$1.66	+8.5%	✓ BEAT

Frequently Asked Questions about NVS

What is NVS's current stock price?

Novartis AG (NVS) is currently trading at $141.61 per share. The stock has moved -0.15% today.

What is the analyst price target for NVS?

The average analyst price target for NVS is $127.00, based on 1 analyst.

What sector is Novartis AG in?

Novartis AG operates in the Healthcare sector, specifically within the Drug Manufacturers - General industry. The company is traded on the NYSE exchange.

What is NVS's market cap?

Novartis AG has a market capitalization of $277.10 billion, making it a mega-cap company.

Does NVS pay dividends?

No, Novartis AG does not currently pay a dividend to shareholders.